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Amyloid-β plaque accumulation in Alzheimer’s disease (AD) is associated with dystrophic
neurite (DN) formation and synapse loss in principal neurons, but interneuron pathology is
less clearly characterized.We compared the responses of neuronal processes immunoreac-
tive for either neuroﬁlament triplet (NF+) or calretinin (CR+) to ﬁbrillar amyloid (Aβ) plaques
in human end-stage and preclinical AD, as well as in APP/PS1 and Tg2576 transgenic
mouse AD models. Neurites traversing the Aβ plaque core, edge, or periphery, deﬁned
as 50, 100, and 150% of the plaque diameter, respectively, in human AD and transgenic
mouse tissue were compared to age-matched human and wild-type mouse controls. The
proportion of NF+ neurites exhibiting dystrophic morphology (DN) was signiﬁcantly larger
than the proportion of dystrophic CR+ neurites in both human AD and transgenic mice
(p < 0.01). Additionally, the number of NF+, but not CR+, DNs, correlated with Aβ plaque
size. We conclude that CR+ interneurons appear to be more resistant than NF+ neurons
to AD-mediated cytoskeletal pathology.
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INTRODUCTION
Alzheimer’s disease (AD) is commonly associatedwith a cascade of
neuronal cytoskeletal alterations – neuroﬁbrillary tangles (NFTs),
neuropil threads and dystrophic neurite (DN) formation, causing
spine and synapse loss – as well as overt neuronal degeneration
(Spires et al., 2005; Adalbert et al., 2009;Vickers et al., 2009). These
pathological changes develop in a characteristic spatiotemporal
progression across the cortex in most human cases (Braak et al.,
2011), and to some extent in AD mouse models (Blanchard et al.,
2003), suggesting a differential subregional and cellular suscep-
tibility to AD. DNs are intimately associated with extracellular
depositions of amyloid β (Aβ), known as plaques (Dickson et al.,
1999; Woodhouse et al., 2009b) and present as swollen tortuous
neurites 10–60 μm in diameter, with variable morphology and
composition depending on the pathological stage of AD (Vickers
et al., 1996; Su et al., 1998; Woodhouse et al., 2009b). In preclini-
cal AD cases and transgenic mice, Aβ plaque-associated DNs are
predominantly labeled with antibodies to neuroﬁlament triplet
proteins (NFs) and α-internexin, whereas in end-stage AD, sub-
groups of DNs contain NFs, abnormal tau protein, or a rim of NFs
around a tau core (Benzing et al., 1993; Su et al., 1996; Dickson
et al., 1999, 2005). This suggests that DN composition may shift
from NF/α-internexin to predominantly tau, as disease progresses
(Blanchard et al., 2003; Vickers et al., 2009). This progression may
imply similar shifts elsewhere in affected neurons.
Neuroﬁlament triplet proteins belong to the type IV inter-
mediate ﬁlament protein family, and, in the neocortex of
many mammalian species, are predominantly expressed by a
pyramidal subpopulation in layers 2–6 making corticocortical
connections (Vickers and Costa, 1992; Hof et al., 1995;
Van der Gucht et al., 2007; Paulussen et al., 2011). The NF
“triplet” refers to three genetically and structurally interrelated
subunits [68 kDa (NF-L), 160 kDa (NF-M), and 200 kDa (NF-
H)] that are typically co-expressed, and which co-polymerize to
form intermediate ﬁlaments (Szaro and Strong, 2010). In the
rat neocortex, NF-immunopositive (NF+) neurons account for
approximately 10–13% of all neurons (Kirkcaldie et al., 2002),
whereas 20–30% of human temporal cortex neurons are NF+
(Hof et al., 1990).
The effect of AD onNF+ neuronal populations has beenwidely
studied as a possible insight to the basis of neuronal vulnerabil-
ity, and perhaps the pathological mechanisms of AD. SMI32, an
antibody which recognizes dephosphorylated epitopes of the NF-
M and NF-H subunits but does not cross-react with tau, labels
a subset of layer 2, 3, and 5 pyramidal neurons which may be
particularly susceptible to neuroﬁbrillary pathology (Lewis et al.,
1987; Morrison et al., 1987; Hof and Morrison, 1990; Hof et al.,
1990, 1995; Mann, 1996). NF+ neurons in superior frontal and
inferior medial temporal association cortices (Hof et al., 1990),
primary and secondary visual cortex (Hof and Morrison, 1990),
and hippocampal and entorhinal regions (Vickers et al., 1992,
1994) show a high degree of vulnerability to NFT formation and
degeneration. Interestingly, cortical neurons that lack the NF-
triplet, including most inhibitory interneurons, do not develop
NFTs and show a much lower susceptibility to degeneration in
AD (Hof et al., 1991, 1993; Fonseca and Soriano, 1995; Sampson
et al., 1997). Conversely, those subpopulations of inhibitory neu-
rons which do express the NF-triplet are more likely to develop
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NFTs in AD (Hof et al., 1993; Sampson et al., 1997; Leuba et al.,
1998).
To further examine if NF+ neurons and their processes are
selectively vulnerable to AD pathology, we performed a morpho-
logical analysis of neurites in early and end-stage AD cases, as
well as in two widely used transgenic mouse models, APP/PS1
and Tg2576, that develop AD-like Aβ plaque pathology. We
also analyzed calretinin-immunopositive (CR+) neurites as a
non-neuroﬁlament comparison: although a small population of
Cajal–Retzius cells in layer 1 are both CR+ and NF+ (Fonseca
and Soriano, 1995), CR+ interneurons in the layers we studied are




Human brain tissue was acquired from the Sun Health Research
Institute (AZ,USA) and theNationalHealth andMedical Research
Council Brain Bank (Adelaide, Australia), meeting all necessary
ethical approvals as previously described (Dickson et al., 1999;
Woodhouse et al., 2009b). Blocks of inferior temporal cortex, a
major site of Aβ deposition (Braak et al., 2011), were immersion-
ﬁxed with either 10% formalin or 4% paraformaldehyde. Human
tissue comprised six sporadic AD cases meeting CERAD diagnos-
tic criteria (“end-stage”AD; Braak stage IV–V), six non-demented
cases with neocortical plaque pathology but no NFTs (i.e., Braak
stage III), termed “preclinical” AD (Price et al., 2009), and ﬁve
age-matched non-demented cases lacking cortical Aβ plaques or
neuroﬁbrillary pathology (Table 1).
MOUSE TISSUE
All mouse procedures were approved by the Animal Ethics Com-
mittee of the University of Tasmania and are in accordance
with the Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purposes. Brieﬂy, 12-month-old Tg2576
(APPSwe670/671; Hsiao et al., 1996), APP/PS1 (APPSwe,PSEN1dE9;
Jankowsky et al., 2004), and age-matched C57BL/6 wild-type mice
(n = 5, for each group) were terminally anesthetized (sodium
pentobarbitone, 140 mg/kg, i.p.), transcardially perfused (0.01 M
phosphate-buffered saline, PBS, then 4% paraformaldehyde in
PBS). Brains were post-ﬁxed for 2 h at 4◦C, before serial 40 μm
coronal sections were cut on a vibratome from bregma −1.00
to −2.50 mm (Franklin and Paxinos, 2008) and immunola-
beled as outlined below. Regions corresponding to the primary
somatosensory cortex were analyzed.
IMMUNOHISTOCHEMISTRY
All immunohistochemical procedures were performed identically.
Sections were blocked for 2 h in 10% goat serum and 0.3%
Triton-X (both Sigma-Aldrich) by volume in 0.01 M PBS at room
temperature, followed by overnight incubation with primary anti-
bodies in blocking solution at 4◦C. Human and mouse cortical
sections were co-immunolabeled with rabbit anti-CR (1:2000,
Millipore) and a cocktail of mouse SMI32 (de-phosphorylated
NF) and SMI312 (phosphorylatedNF; both at 1:2000, Covance) to
visualize CR+ and NF+ subpopulations of interneurons and prin-
cipal neurons, respectively. Sections were then counter-stained
with 0.0125% thioﬂavin-S (Sigma-Aldrich) and 40% ethanol in
0.01 M PBS, to visualize ﬁbrillar Aβ plaques. Species-appropriate
Table 1 | Human brain cases utilized for immunohistochemistry and analysis.
Type Age Gender Postmortem interval (h) Cortical region Cause of death Source* Plaque load (%)
Sporadic AD 92 F 2.25 ITG Pneumonia SHRI 3.59
Sporadic AD 74 F 2.0 ITG Pneumonia SHRI 3.58
Sporadic AD 74 M 2.75 ITG Respiratory arrest SHRI 2.81
Sporadic AD 83 M 2.75 ITG AD SHRI 2.94
Sporadic AD 66 M 2.75 ITG AD SHRI 1.96
Sporadic AD 84 F 3.0 ITG AD SHRI 2.98
Preclinical AD 90 M 2.25 ITG Respiratory arrest SHRI 2.14
Preclinical AD 81 F 3.0 ITG Cardiac arrest SHRI 2.73
Preclinical AD 84 M 3.0 ITG Cardiopulmonary arrest SHRI 3.03
Preclinical AD 78 M 2.25 ITG Postoperative SHRI 1.33
Preclinical AD 91 M 3.0 ITG Cardiac arrest SHRI 1.42
Preclinical AD 74 M 31.5 ITG Cardiac arrest NTRC 2.13
Control 58 M 27.0 TG Cardiac arrest U Syd –
Control 51 M 23.5 TG Pulmonary embolus U Syd –
Control 47 M 27.5 TG Pneumonia U Syd –
Control 65 M 16.0 TG Cardiopulmonary arrest U Syd –
Control 71 M 32.5 TG Postoperative U Syd –
*SHRI, Sun Health Research Institute (AZ, USA); NTRC, NationalTissue Resource Centre (Melbourne, Australia); U Syd, Department of Pathology, University of Sydney
(Australia).
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Alexa 488 and 594 conjugated secondary antibodies (1:500,Molec-
ular Probes) were applied for 2 h at room temperature, followed
by extensive washes and mounting with PermaFluor mounting
medium (Thermo Fisher Scientiﬁc).
ANALYSIS OF NEURITE SUSCEPTIBILITY
For both AD and mouse cortex, three sections per individual were
used, in each of which 10 plaques were chosen (30 plaques per
case/animal) to assess their effects on CR+ and NF− neurites.
Plaques were chosen at random in layers 2–4, which contain the
majority of CR+ interneuron perikarya and processes in humans
(Fonseca and Soriano, 1995; del Rio and DeFelipe, 1997) andmice
(Park et al., 2002), as well as the highest plaque load (Braak and
Braak, 1991). Using previously described criteria for pathologi-
cal cytoskeletal alterations, labeled neurites with focal increases
in diameter, such as swellings, highly undulating trajectories or
with a change in course greater than 90◦ from the original trajec-
tory, were counted as “dystrophic” (Vickers et al., 1996; Dickson
et al., 1999; Knowles et al., 1999; Le et al., 2001; Figures 1A,B).
Labeled neurites that did not meet any of the dystrophic cri-
teria were considered normal. For each plaque, the number of
CR+ and NF+ neurites traversing the core, edge, and periphery
(deﬁned as 50, 100, and 150% of plaque diameter, respectively;
Figures 1C,D) was determined to assess whether these zones dif-
fered in neuropil damage. More than 3000 intact and DNs per
case type were counted. The average plaque area for human AD
(1290 ± 101 μm2) or transgenic mice (1070 ± 67 μm2) was used
FIGURE 1 | Double-immunofluorescence for NFs (SMI312 and SMI32)
and thioflavin-S (A–C) or calretinin and thioflavin-S (D) with a
superimposed template showing the plaque-core, the plaque-edge,
and the periphery. Small arrows (A,C) denote characteristic swellings in
dystrophic neurites, large arrows (B) highlight increased neurite curvature
and tortuosity, while arrowheads (D) show normal-appearing neurites.
Scale bar = 20 μm.
FIGURE 2 | Graphs illustrating the percentage of NF- (gray bars) and
CR- (white bars) immunolabeled dystrophic neurites associated with
fibrillar Aβ plaques at the three zones in AD, preclinical AD,APP/PS1,
andTg2576 transgenic mice, respectively (±SEM).There are signiﬁcantly
more dystrophic NF+ neurites traversing the Aβ plaque core, edge, and
periphery than CR+ dystrophic neurites within all case types (*p < 0.05,
t -test).
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FIGURE 3 | Double-immunofluorescence labeling of representative
thioflavin-S plaques and NF+ neurites from preclinical AD (A,B),
end-stage AD (D,E), APP/PS1 (G,H), and Tg2576 (J,K) transgenic mice
shows classical bulb-like swellings containing neurofilaments indicated
by filled arrowheads in the plaque-core, small arrows at the plaque
edge, and large arrows in the periphery. Normal-appearing neurites in
association with thioﬂavin-S labeled ﬁbrillar plaques are indicated by unﬁlled
arrowheads. A large proportion of NF+ neurites associated with Aβ plaques
are dystrophic (blue fraction: C,F,I,L) and there is extensive neruite loss in
end-stage AD and Tg2576 mice (gray fraction: F,L).
to deﬁne plaque-equivalent areas placed randomly in images of
control tissue using the grid function in ImageJ, to estimate nor-
mal neurite density in these regions. The number of neurites per
plaque was normalized to the mean plaque diameter for each case,
to allow comparisons of proportions between zones. The mean
number of dystrophic and normal neurites in each plaque zone
(core, edge, or periphery) was expressed as a percentage of the
mean control neurite number. Neurite density loss in AD and
transgenic tissue relative to control values was calculated as a per-
centage: 100 × [1 − (total normal and DNs)/(total neurites in
plaque-equivalent control areas)].
To quantify plaque load, ﬁve randomly selected sections of infe-
rior temporal gyrus (ITG) neocortex from pia to the white matter
were collected for each end-stage AD and preclinical AD case,
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FIGURE 4 | Double-immunofluorescence labeling of representative
thioflavin-S plaques and CR+ neurites from preclinical AD (A,B),
end-stage AD (D,E), APP/PS1 (G,H), and Tg2576 (J,K) transgenic mice
shows a relative paucity of swellings containing calretinin (arrows).
Filled arrowheads indicate normal-appearing CR neurites in association
with thioﬂavin-S labeled ﬁbrillar plaques. In most cases, these neurites
appear to elaborate around plaques. A large proportion of CR-ir neurites
associated with Aβ plaques are normal (purple fraction: C,F,I,L) in all case
types and there are comparatively fewer dystrophic neurites (blue fraction:
C,F,I,L).
and an area approximately 1200 μm wide was analyzed in each,
as previously described (Woodhouse et al., 2009a). The percent-
age area that was stained by thioﬂavin-S was then calculated in
ImageJ.
IMAGE ACQUISITION
Images were captured using a Leica DM LB2 epiﬂuorescence
microscope with a cooled CCD Magnaﬁre (Optronics) camera
or on a Zeiss LSM510 confocal microscope equipped with Zen
software and Ar 488, HeNe 543 lasers. All image analysis was
performed using NIH ImageJ (version 1.45p) software.
STATISTICAL ANALYSIS
Statistical analyses for comparisons of groupmeanswas conducted
by one-way analysis of variance (ANOVA) followed by Dunnett’s
post hoc tests or unpaired t-tests as appropriate using GraphPad
Prism software (version 5.0b) with p < 0.05 (CI 95%) considered
signiﬁcant. In some cases, a Pearson product–moment correlation
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was computed to assess the relationship betweenDNnumbers and
mean plaque size. Mean values were reported ± standard error of
the mean (SEM).
RESULTS
CALRETININ-IMMUNOPOSITIVE INTERNEURONS ASSOCIATED WITH
Aβ PLAQUES ARE MORE RESISTANT TO NEURITIC PATHOLOGY THAN
NEUROFILAMENT-IMMUNOREACTIVE NEURONS
A cocktail comprising SMI32 and SMI312 antibodies was used
to label the NF+ subpopulation of neurites, which we assume
are chieﬂy derived from pyramidal cells of cortical layers 2–6
(Van der Gucht et al., 2007; Paulussen et al., 2011). Although
neurites from a subset of basket cells, or projecting ﬁbers from
subcortical and subthalamic regions, would also be NF+ (Hof and
Morrison, 1990; Hof et al., 1990), their fewer numbers and less
extensive neurite ﬁelds indicates that pyramidal neurites make up
the majority of NF+ processes examined in cortical layers 2–4
(Hof et al., 1995).
The number of NF+ and CR+ neurites scored as “dystrophic”
or “normal” were analyzed at 50, 100, and 150% of Aβ plaque
diameters (core, edge, and periphery, respectively) and mean val-
ues were expressed as percentages of mean human and mouse
control values. For all case types analyzed, the percentage of dys-
trophic NF+ neurites was signiﬁcantly higher than CR+ neurites
(Figure 2, p < 0.01, t-test). Of the three zones examined, NF+
DNs were most common at the plaque edge in APP/PS1 mice
(54.6 ± 2.2%) followed by Tg2576 mice (53.2 ± 2.0%), end-
stage AD (40.3 ± 1.7%), and preclinical AD cases (33.4 ± 1.9%;
mean ± SEM). Similarly, CR+ DNs were most prevalent at the
plaque edge in APP/PS1 (25.6 ± 2.5%), Tg2576 (20.5 ± 1.7%),
end-stage (9.6 ± 0.8%), and preclinical (6.7 ± 0.7%) AD cases.
The greatest difference between NF+ and CR+ neurite responses
in all tissue types was in the plaque periphery, where the propor-
tion of DNs was, on average, four times greater for NF+ neurites
compared to CR+ (Figures 2–4). Representative immunolabeled
sections demonstrate much greater dystrophy in NF+ neurites
(Figure 3) than in CR+ neurites (Figure 4).
We also counted normal neurites around Aβ ﬁbrillar deposits
and in control tissue, to estimate absolute neurite loss. Both NF+
(Figure 5A) and CR+ (Figure 5B) neurites exhibited comparable
pronounced neurite density loss in the plaque core in end-stage
AD, preclinical AD, APP/PS1, and Tg2576 cases (p < 0.01, one-
way ANOVA, Dunnett’s post hoc tests). However, no signiﬁcant
loss of CR+ neurites occurred at the plaque edge or periphery
(p > 0.05 in all cases), whereas NF+ neurites showed signiﬁcant
losses in all zones excepting plaque periphery in preclinical AD.
Furthermore, in all four case types, the proportion of normal CR+
neurites at the plaque edge (Figures 4C,F,I,L) was signiﬁcantly
higher than for NF+ neurites (Figures 3C,F,I,L; p < 0.01, t-test).
Interestingly, many normal CR+ neurites in the periphery had
elaborated processes around Aβ plaques, instead of traversing the
plaque or stopping at the plaque border as NF+ neurites often did
(arrowheads, Figure 4).
THE NUMBER OF NF-ir DNs IS DEPENDENT ON Aβ PLAQUE SIZE
ThemeanAβ plaque size was determined in all case types, with the
largest plaques occurring in end-stage AD (1290 ± 101 μm2) and
FIGURE 5 | Graphs showing the percentage neurite density loss for
NF+ (A) and CR+ (B) neurites.There is a signiﬁcant NF+ neurite density
loss for the different case types across all three regions (A, *p < 0.01,
ANOVA with Dunnett’s post hoc test), whereas CR+ neurite density loss
for the different case types was signiﬁcant only in the plaque-core (B,
*p < 0.01). Error bars denote standard error of the mean.
the smallest in preclinical AD (870 ± 93 μm2). In human cases,
the mean number of dystrophic NF+ neurites correlated with Aβ
plaque size in both preclinical (Figure 6A, r = 0.46, p < 0.001,
t-test) and end-stage AD (Figure 6B, r = 0.82, p < 0.001, t-test)
cases. There was a similar pattern in the transgenic mice, with
higher numbers of NF+ DNs associated with larger plaques in
APP/PS1 (Figure 6C, r = 0.72, p < 0.001, t-test; mean plaque
size = 1072 ± 67 μm2) and Tg2576 (Figure 6D, r = 0.39,
p < 0.01, t-test; mean plaque size = 882 ± 118 μm2) ani-
mals. In contrast, CR+ DN counts did not correlate signiﬁcantly
with plaque size in any of the groups (p > 0.05 for all). Fur-
thermore, in human end-stage cases, the total number of NF+
DNs per case correlated with thioﬂavin-S plaque load (Figure 6F,
r = 0.89, p < 0.05), but not in preclinical AD cases (r = 0.17,
p = 0.12).
DISCUSSION
Human AD is characterized by the accumulation of extracel-
lular Aβ plaques and intracellular NFTs comprised chieﬂy of
hyperphosphorylated tau (Braak and Braak, 1991; Braak et al.,
2011). Interestingly, NF+ neurons may be especially vulnerable
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FIGURE 6 |The number of NF+, but not CR+, dystrophic neurites (DN)
was significantly related to Aβ plaque size in both preclinical (A,
**p < 0.001, t -test) and end-stage AD (B, **p < 0.001), as well as in
APP/PS1 (C, **p < 0.001) andTg2576 (D, *p < 0.01, t -test) transgenic
mice. End-stage AD cases had the largest mean Aβ plaque size (E, *p < 0.05,
t -test). (F)The total number of NF+ DNs per case correlated signiﬁcantly with
total Aβ plaque load in end-stage AD cases but not with preclinical cases
(n = 6 each; *p < 0.01, t -test). Error bars denote standard error of the mean.
to developing extensive NFT pathology (Bussiere et al., 2003;
Thangavel et al., 2009), as they accumulate large amounts of
hyperphosphorylated NFs in their perikarya and axons and even-
tually degenerate (Morrison et al., 1987; Vickers et al., 1992, 2009;
Masliah et al., 1993; Mann, 1996; Su et al., 1996; Dickson et al.,
1999; Woodhouse et al., 2009b). However, overt cell death occurs
mostly in end-stage AD, and is absent in many transgenic AD
models, suggesting that cognitive symptoms which manifest years
earlier are due to neuronal dysfunction rather than loss; synaptic
and axonal changes may be the earliest functional disruption.
Thus, we investigated if NF+ neurons were more susceptible to
DN formation at early and end-stages of AD, as well as in APP/PS1
and Tg2576 transgenic mice.
Studies in transgenic AD models have previously shown losses
in dendritic spine density, increases in neurite curvature, sprout-
ing, and varicosities in pyramidal neurondendrites (Knowles et al.,
1999; Le et al., 2001; Adlard and Vickers, 2002; Spires et al., 2005),
as well as axonal disruption (Su et al., 1998; Adalbert et al., 2009;
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Mitew et al., 2010) associated with Aβ plaques. Likewise, in the
current study, we observed a progression of dystrophic changes
in NF+ neurites from early to end-stage human AD, paralleled
in both APP/PS1 and Tg2576 transgenic mice lines. There was
an increase in the proportion of dystrophic NF+ neurites across
all three case types, most prominently at the plaque periphery,
then the surrounding neuropil and the plaque core, respectively
(Figure 2). Concomitantly, the total neurite number relative to
age-matched controls decreased markedly, due to depletion in
the plaque core and edge (Figure 5). This agrees with previ-
ous work showing reduced axonal density and total length in
AD plaque-associated neuropil (DeWitt and Silver, 1996). The
most severe changes occurred in end-stage AD, followed by the
Tg2576 and APP/PS1 mouse models, and the least severe in pre-
clinical human AD. The ﬁnding that Aβ plaques damage neurites
some distance away (i.e., plaque periphery) also concurs with pre-
vious studies (Knowles et al., 1999; Le et al., 2001); retrograde
swellings in axons have been reported several hundred microns
from plaques in vivo (Vickers et al., 1996; Adalbert et al., 2009).
This implies that dystrophic changes propagate along neurites, or
that plaques possess a “halo” of toxicity that extends more distally
(Kofﬁe et al., 2009).
In contrast, CR+ neurites were less dystrophic in all three
plaque zones examined,with signiﬁcantlymore normal-appearing
CR+ neurites at the edge and in the periphery, but fewer total
neurites (normal + dystrophic) in plaque cores. Unlike NF+ neu-
rites, which tended to traverse plaque cores, often showing signs
of dystrophy, CR+ neurites appeared to either terminate at the
plaque periphery, or much more commonly, to elaborate around
it (Figure 4). Furthermore, unlike NF+ DNs, counts of CR+ DNs
did not correlate with plaque size (Figure 6). In addition to their
potential focal toxicity, larger plaques may physically distort the
surrounding neuropil and cause structural alterations to neurites
like increased curvature (Knowles et al., 1999; Woodhouse et al.,
2005;Meyer-Luehmann et al., 2008). Therefore, CR+ neuritesmay
be more resistant to physical damage, or may have a higher capac-
ity for structural remodeling and regeneration. We have recently
shown that they exhibit greater structural plasticity than GFP+
pyramidal neurons near focal neocortical injury, rearranging their
dendritic processes away from the injury site toward unaffected
neuropil (Blizzard et al., 2011). Likewise, in vivo imaging of adult
murine cortex shows that unlike pyramidal neurons, inhibitory
neurons frequently extend new dendrites and remodel existing
branches (Lee et al., 2008). The results of the present study suggest
that fewer CR+ neurites traverse plaque cores, while many elab-
orate processes around plaques (Figure 4), potentially indicating
dynamic restructuring away from these localized sites of neuropil
injury, as previously described (Blizzard et al., 2011).
It is not clear why NF+ neurons are selectively vulnerable to
AD pathology. One possibility is that elevated Aβ levels interfere
with normal NF regulation and transport. Indeed, increased levels
of phosphorylation, either at endogenous or at novel NF phos-
phorylation sites (Liao et al., 2004), are a relatively early event in
the pathogenesis of human AD (Wang et al., 2001; Rudrabhatla
et al., 2010) and transgenic models (Vickers et al., 1994; Yang et al.,
2009). Such aberrant hyperphosphorylation of NFs in AD is likely
mediated by abnormal hyperactivity of kinases such as Erk1 and 2
(Veeranna et al., 2004), Cdk5 (Shea et al., 2004), and GSK3β (Chen
et al., 2005), or the decreased activity of phosphatases such as PP-
2A and 1 (Rudrabhatla et al., 2009). As phosphorylation mediates
many aspects of NF function including axonal transport of NFs
and radial growth of axons, dysregulation of this system could
critically impact cytoskeletal integrity in AD (Shea and Chan,
2008). Higher NF expression and phosphorylation is also associ-
ated with maturation of neurons resulting in larger axonal caliber
and myelination, effectively increasing structural stability at the
expense of plasticity. Therefore, a combination of lower capacity
for structural remodeling and a perturbed phosphorylation bal-
ance could primeNF+ neurites for DN formation and cytoskeletal
dysfunction in AD.
In conclusion, we report that CR+ interneurons are less sus-
ceptible than NF+ neurons to neurite damage mediated by Aβ
plaques, in both human AD cases and transgenic mouse models.
It is likely that a combination of factors, such as a higher capacity
for structural remodeling and regeneration following focal injury,
contribute to this relative resistance. This study contributes to pre-
vious work showing that NFs may predispose the subpopulations
of neurons that express them to structural damage inAD (Hof and
Morrison, 1990; Hof et al., 1990, 1993; Vickers et al., 1996, 2009;
Sampson et al., 1997).
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